Distinct metabolic susceptibilities (beta-cell dysfunction, insulin resistance (IR), and impaired incretin response) underlie type 2 diabetes (T2D). However, their relationships with habitual lifestyle behaviors are underexplored. This study integrated high-resolution lifestyle data from wearable…
Continue Reading
What You Should Know:
– Sequel Med Tech, a company developing state-of-the-art insulin delivery technologies, announced a commercial development agreement with Abbott.
– The collaboration aims for the future integration of Sequel’s twiist™ Automated Insulin Delivery…
Continue Reading
Pharmaceutical and diagnostics giant Roche announced it will fund a $550 million diagnostic center in Indianapolis by 2030.The manufacturing hub will produce Roche’s continuous glucose monitoring (CGM) systems for diabetes management.
The center will include…
What You Should Know:
– Abbott, a provider of continuous glucose monitoring (CGM) biowearable technology, has announced a landmark agreement with Epic Systems, a major provider of electronic health records (EHR).
– The first-of-its-kind collaboration for…
Continue Reading
What You Should Know:
– Sequel Med Tech, LLC, known for its innovative insulin delivery technology, and Senseonics Holdings, Inc., developer of long-term implantable continuous glucose monitoring (CGM) systems, announced a significant commercial development agreement.
–…
Continue Reading
Early Innovation Matters: What I Learned Building a Glucose Sensor in High SchoolBy Max Kopp
Max Kopp is a high school researcher who is focused on biomedical engineering and non-invasive sensing systems. He is…
Extended Wear CGM Innovation Redefines Diabetes Management
Dexcom has reached a significant milestone with FDA clearance for its G7 15-Day continuous glucose monitoring system for adults 18 and older. This next-generation device extends wear time…
Glucose monitoring specialist Dexcom announced it received FDA clearance for its G7 15 Day continuous glucose monitoring (CGM) system for people 18 and older with type 1, type 2 and gestational diabetes. G7 15 Day,…
Continue Reading
What You Should Know:
– Dexcom, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for individuals over the age of 18…
Continue Reading
Cardiometabolic digital diagnostics company Nanowear announced a licensing and data partnership with glucose monitoring specialist Dexcom to integrate glucose data from the Dexcom G7 into its SimpleSense nanotechnology-enabled wearable. Nanowear offers home-based, AI-enabled digital diagnostics…
Continue Reading
